146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trial
Elizabeth Fitzpatrick, P. McNally, Rachel Cregan, B. Elnazir, B. Linnane, D. Cox, Jane C. Davies(Guy's and St Thomas' NHS Foundation Trust), P. O’Regan(University College Cork), E. McKone, L. Kirwan(Cystic Fibrosis Ireland), M. Williamson
Cited by 0
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
|Clinical Infectious Diseases|2022|98